Grant of Share Options

Cathay International Holdings Limited

("Cathay" or the "Company")

Grant of Share Options

Hong Kong, 7 April 2014 - Cathay International Holdings Ltd. (LSE: CTI.L), an investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China, today announces that on 1 April 2014, the Company granted 7,390,353 options under a share option plan (the "Share Option Plan") approved by shareholders of the Company on 3 June 2010. The 7,390,353 options granted to certain members of the Group's management and employees represent approximately 39.74% of the options currently available under the Share Option Plan. Of the 7,390,353 options granted, the share options granted to directors and senior executives of the Group are as follows:

The exercise price of the options of 37.275 pence per share equates to the average closing mid-market price of the Company's common shares for the 30 trading days immediately prior to the date of grant. The options have a three years vesting period and are exercisable on or before the fifth anniversary of the date of the grant, subject to certain exercise conditions aligned to the Group's results and performance.

For further enquiries, please contact:

Cathay International Holdings Limited

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

Tel: +852 2828 9289

Consilium Strategic Communications

Mary-Jane Elliott / Amber Bielecka / Lindsey Neville

Tel: +44 (0)203 709 5708

About Cathay

Cathay International Holdings Limited (LSE: CTI.L), focused on the People's Republic of China ("PRC"), is an investment holding company and a leading investor in the growing healthcare sector in the PRC. The Group employs more than 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen.

Cathay aims to identify investment opportunities with emphasis on high growth healthcare markets and build them into market sector leaders, with a clear exit strategy. Cathay has demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen, China's leading specialty pharmaceutical company focused on rheumatology and dermatology; Haizi, a company engaged in the manufacture, marketing and sale of inositol and DCP; and Yangling, a company engaged in the extract and trading of key active ingredients for healthcare products, including inositol. To complement its healthcare portfolio, Cathay has a research and product development business focused on bringing new products to the growing Chinese market.

Cathay also has a private equity investment arm focused on minority investment opportunities and a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk